These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Gradishar WJ Oncology; 2005; 69(1):1-9. PubMed ID: 16088229 [TBL] [Abstract][Full Text] [Related]
3. Tamoxifen, screening and new oestrogen receptor modulators. Neven P; Vergote I Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559 [TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors for the treatment and prevention of breast cancer. Kalidas M; Brown P Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070 [TBL] [Abstract][Full Text] [Related]
5. Prevention of hormone-related cancers: breast cancer. Dunn BK; Wickerham DL; Ford LG J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398 [TBL] [Abstract][Full Text] [Related]
6. Current concepts in breast cancer chemoprevention. Chlebowski RT Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912 [TBL] [Abstract][Full Text] [Related]
7. Vascular effects of aromatase inhibitors: data from clinical trials. Howell A; Cuzick J J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188 [TBL] [Abstract][Full Text] [Related]
11. The influence of endocrine treatments for breast cancer on health-related quality of life. Buijs C; de Vries EG; Mourits MJ; Willemse PH Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425 [TBL] [Abstract][Full Text] [Related]
12. Exemestane for primary prevention of breast cancer in postmenopausal women. Zhang Y; Simondsen K; Kolesar JM Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103 [TBL] [Abstract][Full Text] [Related]
13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
14. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782 [TBL] [Abstract][Full Text] [Related]
15. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
16. Tamoxifen, raloxifene and the prevention of breast cancer. Bentrem DJ; Craig Jordan V Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504 [TBL] [Abstract][Full Text] [Related]
17. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
18. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601 [TBL] [Abstract][Full Text] [Related]
19. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV; Goldstein SR Menopause; 2010; 17(3):642-53. PubMed ID: 20107426 [TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. Mocellin S; Pilati P; Briarava M; Nitti D J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]